May 25, 2009

Eli Lilly Launches Two Late Stage Clinical Trials for Alzheimer's (LY2062430)

LY2062430 is now known as solanezumab (i).

These new clinical trials being offered by Eli Lilly are open to those suffering from Alzheimer's disease. The study intends to enroll 2,000 participants.

The good news here is that there is no upper age limit (anyone older than 55 could qualify), and the clinical trial locations are likely to cover most of the United States. The goal of enrolling 2,000 participants is very ambitious and good news to those suffering from Alzheimer's.
"Current therapies available to treat Alzheimer's disease may help with symptoms, but they haven't been proven to change the disease progression," said Eric Siemers M.D., Medical Director, Alzheimer's disease research for Eli Lilly and Company. "Biomarker results from a Phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of progression of Alzheimer's disease."
Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease. The trials are called EXPEDITION and EXPEDITION 2.
EXPEDITION 2 is now recruiting new participants. To find out all the details about the phase III clinical trial go here.

EXPEDITION is not yet open, but you can get all the details by following this link.

Related Content

Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2)

Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD. LY2062430 (solanezumab *USAN adopted name, INN pending) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo.

Each patient's participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
Contact: Eli Lilly
For additional information regarding investigative sites for this trial (locations), contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
EXPEDITION will be conducted in Argentina, Brazil, Canada, Japan, and United States. EXPEDITION 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States. 

Subscribe to the Alzheimer's Reading Room

Bob DeMarco
Bob DeMarco is the Founder of the Alzheimer's Reading Room (ARR). Bob is a recognized Influencer, speaker, and expert in the Alzheimer's and Dementia Community Worldwide. The Alzheimer's Reading Knowledge Base contains more than 4,000 articles, and the ARR has more than 343,000 links on the Internet. Bob lives in Delray Beach, FL.
Search more than 4,000 original articles on Alzheimer's and dementia in the Alzheimer's Reading Room Knowledge Base